Manulife Financial Corporation vs Zimmer Biomet Holdings Inc — how do they compare? Manulife Financial Corporation trades at $42.51 (market cap $69.96B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Manulife Financial Corporation is far larger — about 4× Zimmer Biomet Holdings Inc's market cap, and Manulife Financial Corporation pays the higher dividend (3.14%). Which is the better fit depends on your goals.
| MFC | ZBH | |
|---|---|---|
Market Cap | $69.96B | $17.36B |
Sector | Financials | Health |
52-Week High | $43.39 | $107.71 |
52-Week Low | $29.90 | $79.58 |
Enterprise Value | $66.52B | $24.40B |
Dividend Yield | 3.14% | 1.07% |
Signals from Pluang's Aura AI — not financial advice
MFC trades at $42.83, down 1.29% today, with a bullish technical signal supported by moving averages. The company reported revenue of $53.01B in 2025 and net income of $5.78B, with a P/E of 17.39. Recent news highlights AI advancements and strong Asia performance, while Q1 2026 earnings missed expectations. Analyst consensus is 57% buy with no sell ratings.
Outlook remains positive driven by AI initiatives and Asia growth, but risks include Q1 earnings miss and regulatory scrutiny. The stock offers steady profitability and dividend income, yet faces headwinds from wealth management outflows and competitive pressures in core markets.
No Aura AI signal available yet.
Trailing returns across standard periods
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →